Recent Analysts’ Ratings Updates for Celldex Therapeutics (CLDX)

A number of research firms have changed their ratings and price targets for Celldex Therapeutics (NASDAQ: CLDX):

• 9/30/2024 – Celldex Therapeutics is now covered by analysts at The Goldman Sachs Group, Inc.. They set a “neutral” rating and a $45.00 price target on the stock.
• 9/27/2024 – Celldex Therapeutics was downgraded by analysts at Wolfe Research from an “outperform” rating to a “peer perform” rating.
• 9/26/2024 – Celldex Therapeutics was upgraded by analysts at Wells Fargo & Company from a “hold” rating to a “strong-buy” rating.
• 9/26/2024 – Celldex Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
• 9/25/2024 – Celldex Therapeutics had its “outperform” rating reaffirmed by analysts at Wolfe Research. They now have a $51.00 price target on the stock.
• 9/16/2024 – Celldex Therapeutics had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $67.00 price target on the stock.
• 9/9/2024 – Celldex Therapeutics had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $67.00 price target on the stock.
• 8/12/2024 – Celldex Therapeutics had its price target raised by analysts at Wells Fargo & Company from $35.00 to $37.00. They now have an “equal weight” rating on the stock.
• 8/12/2024 – Celldex Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.

Celldex Therapeutics Trading Down 4.7 %

Shares of NASDAQ:CLDX traded down $1.59 during midday trading on Tuesday, reaching $32.40. The company had a trading volume of 992,550 shares, compared to its average volume of 857,051. The company’s 50 day moving average price is $38.30 and its 200 day moving average price is $38.18. The stock has a market cap of $2.15 billion, a P/E ratio of -11.37 and a beta of 1.56. Celldex Therapeutics, Inc. has a 52-week low of $22.11 and a 52-week high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.05. Celldex Therapeutics had a negative return on equity of 23.66% and a negative net margin of 1,809.18%. The firm had revenue of $2.50 million for the quarter, compared to analysts’ expectations of $1.13 million. Research analysts forecast that Celldex Therapeutics, Inc. will post -2.5 EPS for the current fiscal year.

Institutional Trading of Celldex Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Celldex Therapeutics in the second quarter worth approximately $76,000. Headlands Technologies LLC bought a new stake in Celldex Therapeutics in the first quarter valued at $147,000. CANADA LIFE ASSURANCE Co boosted its holdings in Celldex Therapeutics by 26.4% in the first quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock valued at $192,000 after acquiring an additional 955 shares in the last quarter. Ameritas Investment Partners Inc. boosted its holdings in Celldex Therapeutics by 34.3% in the first quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company’s stock valued at $260,000 after acquiring an additional 1,582 shares in the last quarter. Finally, Los Angeles Capital Management LLC bought a new stake in Celldex Therapeutics in the first quarter valued at $283,000.

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.